PharmaJet, Inc.

Company Summary

The PharmaJet Stratis® innovative Needle-Free Injector has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines intramuscularly or subcutaneously.

Transaction Overview

In June 2018, PharmaJet has entered into an exclusive global distribution agreement with Mundipharma.
The agreement involves a 5-year stock order commitment by Mundipharma worth over $50 million.

‍

Significance of the Transaction

"The agreement grants PharmaJet access to over 120 countries and 6 continents through Mundipharma global distribution network. The partnership serves as an inflection point in the Company’s global growth strategy."

Healthios Role

If you would like to learn more information about this transaction contact us below.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Partnering

PharmaJet, Inc.

Has completed a global distribution agreement with

The undersigned acted as exclusive advisor to PharmaJet